In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Incyte (INCY – Research Report), with a price target of $108.00. The company’s shares closed last Wednesday at $68.28.
According to TipRanks.com, Benjamin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.2% and a 30.5% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.
Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $90.36, a 35.2% upside from current levels. In a report issued on February 8, Truist Financial also reiterated a Buy rating on the stock with a $95.00 price target.
The company has a one-year high of $94.50 and a one-year low of $61.91. Currently, Incyte has an average volume of 2.21M.
Based on the recent corporate insider activity of 106 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Read More on INCY:
- Murphy USA (MUSA) Receives a Hold from Jefferies
- Western Digital (WDC) Receives a Rating Update from a Top Analyst
- Wells Fargo Believes Arch Capital Group (ACGL) Still Has Room to Grow
- Stifel Nicolaus Thinks Meta Platforms’ Stock is Going to Recover
- AZEK Company (AZEK) Gets a Buy Rating from Stifel Nicolaus